Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Copper peptides, specifically GHK-Cu, are discussed as a potential addition to hair loss treatments, possibly working synergistically with Minoxidil to convert vellus hair into terminal hair. The effectiveness and credibility of copper peptides are questioned due to the lack of widespread discussion and potential conflict of interest from the product's creator.

The user documented hair regrowth progress over 8 weeks using Minoxidil foam twice daily and weekly microneedling. Another user suggested adding finasteride for better results.

GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.

A 28-year-old male experienced significant hair regrowth at the temples using 5mg Minoxidil and 0.5mg Dutasteride daily since January, with no side effects. He plans to continue the treatment indefinitely to maintain results.

A user in the UAE is facing customs issues with ordering Fluridil (Eucapil) and is considering ordering smaller quantities or switching to Pyrilutamide. They are also using finasteride daily to maintain hair and are unsure of Fluridil's effectiveness.

TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.

The conversation discusses the use of spironolactone, cyproterone acetate, and bicalutamide for hair loss, with concerns about side effects like gynecomastia and depression. Topical spironolactone is considered safe for men and effective when combined with regular treatments.

Peptides like GHK-Cu, BPC-157, and TB-500 have significantly reduced hair loss, with GHK-Cu being particularly effective. The discussion also covers the high cost of these peptides and explores more affordable purchasing options.

A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.

Celery juice is discussed as a potential treatment for crown balding, with skepticism from users. The conversation highlights differences between alopecia areata and male pattern baldness.

A treatment containing Wnt and Follistatin was found to be safe and effective for hair regrowth in a Phase 1 clinical trial. Specific treatments discussed include Minoxidil, Finasteride, and RU58841.

Creatine might speed up hair loss in those prone to male pattern baldness, possibly due to increased DHT levels. Some users experience no issues when using creatine with treatments like finasteride, minoxidil, or dutasteride.

The user noticed new hair growth after using topical minoxidil and undergoing 2 GFC sessions, along with using caffeine shampoo. They plan to start using topical finasteride and minoxidil and are inquiring if shampooing is necessary before application.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

The user experienced significant hair regrowth using dutasteride (0.5 mg three times a week) and RU58841 (5% once a day), with no side effects reported from RU58841. They are considering increasing the RU58841 dose or adding minoxidil for further improvement.

The user is using Dutasteride, Minoxidil, microneedling, RU58841, and tretinoin for hair loss. They are experiencing shedding but notice new hair growth and are curious about the timing of future shedding phases.

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

Rapamycin, finasteride, and minoxidil are discussed as a strategy for hair loss prevention and reversal. Pulsed dosing of rapamycin is suggested to avoid conflicting effects with minoxidil.

The conversation discusses the effectiveness of adding RCP (redensyl, capixyl, procapil) to a hair loss treatment regimen that includes minoxidil and finasteride. Users share experiences, suggesting RCP may not be as effective as minoxidil, but could be useful for creating topical solutions.

A 21-year-old is experiencing severe hair shedding after 8 months of using topical minoxidil and oral finasteride, losing all progress made. Others advise that shedding is normal and temporary, suggesting to continue the treatment and ensure the use of genuine products.

The conversation discusses hair loss treatments, specifically oral minoxidil (2.5mg), dutasteride (0.5mg every other day), and ketoconazole. The user reports slow progress but significant hair growth after adding ketoconazole to their routine.

The user has tried various hair loss treatments including topical minoxidil, oral finasteride, oral dutasteride, oral minoxidil, and exosome therapy, but none have been effective. They suspect trichodynia might be preventing these treatments from working.

PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

A user shared their 2-month progress using finasteride (1mg) daily, topical minoxidil (5%) daily, and dermarolling twice a week, noting some regrowth and satisfaction with the results. Another user complimented the progress, and the original poster detailed their dermarolling routine.

Maneup GHK-Cu peptide was used for hair loss, resulting in some hair growth in the receded hairline, but the new hairs were dry and split easily. Users discussed their experiences with this treatment.

RU58841 is praised for its fast-acting effects on hair regrowth, with the user also using finasteride, minoxidil, dutasteride, and GHKcu. Some users report side effects like chest pain, while others see positive results, but it's unclear which treatment is most effective due to multiple compounds being used simultaneously.

Aminexil/Kopexil may help reduce hair loss by addressing perifollicular fibrosis in androgenetic alopecia, but it lacks the extensive clinical backing of finasteride and minoxidil. Some users find it effective, but availability and cost are issues, especially in the US where it's not FDA-approved.

A 26-year-old used high-dose dutasteride monotherapy for two years, reporting significant hair regrowth without side effects. The user avoided combining it with minoxidil due to cardiac risk concerns.